197 related articles for article (PubMed ID: 33805264)
21. [
Lawal IO; Popoola GO; Mahapane J; Kaufmann J; Davis C; Ndlovu H; Maserumule LC; Mokoala KMG; Bouterfa H; Wester HJ; Zeevaart JR; Sathekge MM
Biomolecules; 2020 Dec; 10(12):. PubMed ID: 33287237
[TBL] [Abstract][Full Text] [Related]
22.
Luo Y; Cao X; Pan Q; Li J; Feng J; Li F
J Nucl Med; 2019 Dec; 60(12):1724-1729. PubMed ID: 31101745
[No Abstract] [Full Text] [Related]
23. Targeting CXCR4 with [
Lapa C; Kircher S; Schirbel A; Rosenwald A; Kropf S; Pelzer T; Walles T; Buck AK; Weber WA; Wester HJ; Herrmann K; Lückerath K
Oncotarget; 2017 Nov; 8(57):96732-96737. PubMed ID: 29228566
[TBL] [Abstract][Full Text] [Related]
24. Impact of Tumor Burden on Normal Organ Distribution in Patients Imaged with CXCR4-Targeted [
Serfling SE; Lapa C; Dreher N; Hartrampf PE; Rowe SP; Higuchi T; Schirbel A; Weich A; Hahner S; Fassnacht M; Buck AK; Werner RA
Mol Imaging Biol; 2022 Aug; 24(4):659-665. PubMed ID: 35312939
[TBL] [Abstract][Full Text] [Related]
25. Diagnostic value of [ 68 Ga]Ga-Pentixafor PET/CT in malignant melanoma: a pilot study.
Manafi-Farid R; Mahini M; Mirshahvalad SA; Fallahi B; Fard-Esfahani A; Emami-Ardekani A; Eftekhari M; Mousavi SA; Beiki D
Nucl Med Commun; 2024 Mar; 45(3):221-228. PubMed ID: 38214076
[TBL] [Abstract][Full Text] [Related]
26. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
27. [
Schwarzenböck SM; Stenzel J; Otto T; Helldorff HV; Bergner C; Kurth J; Polei S; Lindner T; Rauer R; Hohn A; Hakenberg OW; Wester HJ; Vollmar B; Krause BJ
Oncotarget; 2017 Nov; 8(56):95606-95619. PubMed ID: 29221153
[TBL] [Abstract][Full Text] [Related]
28.
Kraus S; Dierks A; Rasche L; Kertels O; Kircher M; Schirbel A; Zovko J; Steinbrunn T; Tibes R; Wester HJ; Buck AK; Einsele H; Kortüm KM; Rosenwald A; Lapa C
J Nucl Med; 2022 Jan; 63(1):96-99. PubMed ID: 34049979
[TBL] [Abstract][Full Text] [Related]
29. MIB-1 Index-Stratified Assessment of Dual-Tracer PET/CT with
Sampathirao N; Basu S
J Nucl Med Technol; 2017 Mar; 45(1):34-41. PubMed ID: 28154019
[TBL] [Abstract][Full Text] [Related]
30. Chemokine Receptor CXCR4-Targeted PET/CT With 68Ga-Pentixafor Shows Superiority to 18F-FDG in a Patient With Waldenström Macroglobulinemia.
Luo Y; Pan Q; Feng J; Cao X; Li F
Clin Nucl Med; 2018 Jul; 43(7):548-550. PubMed ID: 29742593
[TBL] [Abstract][Full Text] [Related]
31. First Experience with Chemokine Receptor CXCR4-Targeted PET Imaging of Patients with Solid Cancers.
Vag T; Gerngross C; Herhaus P; Eiber M; Philipp-Abbrederis K; Graner FP; Ettl J; Keller U; Wester HJ; Schwaiger M
J Nucl Med; 2016 May; 57(5):741-6. PubMed ID: 26769866
[TBL] [Abstract][Full Text] [Related]
32. Role of PET/CT and Therapy Management of Pancreatic Neuroendocrine Tumors.
Calabrò D; Argalia G; Ambrosini V
Diagnostics (Basel); 2020 Dec; 10(12):. PubMed ID: 33297381
[TBL] [Abstract][Full Text] [Related]
33. [
Watts A; Singh B; Singh H; Bal A; Kaur H; Dhanota N; Arora SK; Mittal BR; Behera D
Eur J Nucl Med Mol Imaging; 2023 Mar; 50(4):1216-1227. PubMed ID: 36482077
[TBL] [Abstract][Full Text] [Related]
34. Preliminary evidence of imaging of chemokine receptor-4-targeted PET/CT with [
Pan Q; Luo Y; Zhang Y; Chang L; Li J; Cao X; Li J; Li F
EJNMMI Res; 2020 Aug; 10(1):89. PubMed ID: 32757068
[TBL] [Abstract][Full Text] [Related]
35. Functional nodules in primary aldosteronism: identification of CXCR4 expression with
Gao Y; Ding J; Cui Y; Li T; Sun H; Zhao D; Zhang Y; Huo L; Tong A
Eur Radiol; 2023 Feb; 33(2):996-1003. PubMed ID: 36070092
[TBL] [Abstract][Full Text] [Related]
36. Reduced splenic uptake on
Kraus S; Klassen P; Kircher M; Dierks A; Habringer S; Gäble A; Kortüm KM; Weinhold N; Ademaj-Kospiri V; Werner RA; Schirbel A; Buck AK; Herhaus P; Wester HJ; Rosenwald A; Weber WA; Einsele H; Keller U; Rasche L; Lapa C
Theranostics; 2022; 12(13):5986-5994. PubMed ID: 35966583
[TBL] [Abstract][Full Text] [Related]
37. Imaging of C-X-C Motif Chemokine Receptor 4 Expression in 690 Patients with Solid or Hematologic Neoplasms Using
Buck AK; Haug A; Dreher N; Lambertini A; Higuchi T; Lapa C; Weich A; Pomper MG; Wester HJ; Zehndner A; Schirbel A; Samnick S; Hacker M; Pichler V; Hahner S; Fassnacht M; Einsele H; Serfling SE; Werner RA
J Nucl Med; 2022 Nov; 63(11):1687-1692. PubMed ID: 35241482
[TBL] [Abstract][Full Text] [Related]
38. Prognostic significance of
Kuyumcu S; Isik EG; Tiryaki TO; Has-Simsek D; Sanli Y; Buyukkaya F; Özkan ZG; Kalayoglu-Besisik S; Unal SN
Ann Nucl Med; 2021 Oct; 35(10):1147-1156. PubMed ID: 34185263
[TBL] [Abstract][Full Text] [Related]
39. Assessment of Central Nervous System Lymphoma Based on CXCR4 Expression In Vivo Using 68Ga-Pentixafor PET/MRI.
Starzer AM; Berghoff AS; Traub-Weidinger T; Haug AR; Widhalm G; Hacker M; Rausch I; Preusser M; Mayerhoefer ME
Clin Nucl Med; 2021 Jan; 46(1):16-20. PubMed ID: 33208624
[TBL] [Abstract][Full Text] [Related]
40.
Wang H; Zhu W; Ren S; Kong Y; Huang Q; Zhao J; Guan Y; Jia H; Chen J; Lu L; Xie F; Qin L
Front Oncol; 2021; 11():693640. PubMed ID: 34249748
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
